REGULATORY

• Japan to Research Duration of COVID-19 Vaccine Efficacy: Minister
  March 31, 2021

• Label Revisions Ordered for Utemerin and More Drugs, 1st Update for Zolgensma
  March 31, 2021

• 1.35% of Tokyo Residents Have Coronavirus Antibodies: MHLW
  March 31, 2021

• Govt’s Drug Development Panel Adopts 5 Priority Topics for Discussion
  March 31, 2021

• Govt to Set Up Taskforce to Spur Development of Japan-Made Vaccines
  March 30, 2021

• Japan Gives Up on Setting New Generic Target by March as Manufacturing Scandals Weigh
  March 30, 2021

• LDP League Submits Request to Reinstate HPV Vaccine Promotion
  March 30, 2021

• MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
  March 30, 2021

• Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
  March 29, 2021

• Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
  March 29, 2021

• 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
  March 29, 2021

• Nichi-Iko Starting Marketing Operations from March 29
  March 29, 2021

• LDP Group to Submit Request for HPV Vaccine Promotion Resumption
  March 26, 2021

• Chuikyo to Compile Reimbursement Rule for Therapeutic Apps by Year-End
  March 25, 2021

• Chuikyo Members Rail against Generic Manufacturing Scandals
  March 25, 2021

• Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
  March 25, 2021

• 6.1% of Hospitals Have Established Formularies: Chuikyo Survey
  March 25, 2021

• Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
  March 25, 2021

• MHLW Notifies of Guidelines on Use of Registry Data in Regulatory Submissions
  March 25, 2021

• Toyama Govt to Probe Repeated Failures to Discover Nichi-Iko’s GMP Violations
  March 25, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 151
• 152
• 153
• 154
• 155
• 156
• 157
• 158
• 159
• …
• Next ›
• 最終 »